CC chemokine ligand 18 correlates with malignant progression of prostate cancer

CC 趋化因子配体 18 与前列腺癌恶性进展相关

阅读:5
作者:Guo Chen, Yu-xiang Liang, Jian-guo Zhu, Xin Fu, Yan-fei Chen, Ru-jun Mo, Liang Zhou, Hao Fu, Xue-cheng Bi, Hui-chan He, Sheng-bang Yang, Yong-ding Wu, Fu-neng Jiang, Wei-de Zhong

Aim

CC chemokine ligand 18 (CCL18) promotes malignant behaviors of various human cancer types. However, its involvement in human prostate cancer has not been fully elucidated. The aim of this study was to investigate the role of CCL18 in PCa.

Conclusions

Our data offer the convincing evidence that the upregulation of CCL18 may be involved in the malignant progression of PCa.

Methods

Expression of CCL18 at mRNA and protein levels was detected using real-time qRT-PCR and immunohistochemistry analysis. We analyzed the associations of CCL18 expression with clinical features of human PCa. The effects of PCa cell migration, invasion, and apoptosis were tested. The efficiency of CCL18 on prostate tumor growth was assessed in a subcutaneous xenograft model.

Results

CCL18 expression was upregulated (both P < 0.01) in PCa tissues compared with those in noncancerous prostate tissues. CCL18 upregulation was correlated with high Gleason score (P = 0.034) of patients with PCa. rCCL18 stimulation in PCa cells promoted cell migration and invasion but decreased DU145 cells apoptosis rate. Furthermore, subcutaneous homografts models showed the increased tumor growth and tumor vascularization with the CCL18 stimulation, and the expression of Ki67, PCNA, and CD31 in CCL18 stimulation mice was also significantly increased. Conclusions: Our data offer the convincing evidence that the upregulation of CCL18 may be involved in the malignant progression of PCa.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。